Syncom Formulations Managing Director Vijay Shankarlal Bankda will step down from his role effective August 11, 2026, marking a significant leadership change for the pharmaceutical manufacturer. The resignation, received by the company on August 8, 2026, at 2:35 PM, is part of a planned succession strategy rather than a result of any dispute with the Board or management.

The company disclosed the development under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing was submitted to both the BSE Limited and the National Stock Exchange of India Limited. Additionally, the disclosure aligns with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Leadership Transition Details

Vijay Shankarlal Bankda, who also serves as a promoter and founder of the company, tendered his resignation from the office of Managing Director and consequently from the Directorship. In his resignation letter, Bankda described his tenure as a privilege and highlighted the opportunity to work with the Board, employees, and stakeholders to strengthen the company’s long-term vision.

The key details of the resignation are outlined below:

Bankda confirmed that his decision was voluntary and did not arise from any disagreement with the Board, management, or any other material reason. He expressed confidence that the existing leadership team would continue to guide Syncom Formulations toward sustained growth.

Board Acknowledgement

The Board of Directors acknowledged the resignation and placed on record its appreciation for Bankda’s exemplary leadership, strategic vision, and dedicated service. Under his stewardship, the company reportedly strengthened its operations and governance standards while pursuing sustainable growth.

Vaishali Agrawal, Company Secretary and Compliance Officer, signed the disclosure on behalf of the company. The Board has requested the necessary statutory and regulatory formalities be completed to effectuate the change in leadership.

Syncom Formulations has accepted the resignation of Rahul Vijay Bankda as Chief Financial Officer, effective August 11, 2026. The company disclosed that Bankda is moving to a different professional responsibility within the organization, ensuring continuity of leadership without external recruitment. This internal transition suggests stability in financial oversight despite the change in title.

The resignation was received by the company on August 8, 2026, at 11:24 AM. The Board of Directors acknowledged the resignation and placed on record its appreciation for Bankda’s contributions during his tenure. The board noted that he will continue to be associated with the company in a different capacity.

Bankda stated in his resignation letter that the decision arises from his choice to undertake a new role within the organization. He explicitly confirmed that the resignation does not stem from any disagreement with the Board of Directors or management, nor is it attributable to any other material reason.

Regulatory Disclosure Details

The company made the disclosure pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing also referenced SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Vaishali Agrawal, Company Secretary and Compliance Officer, signed the intimation to the Bombay Stock Exchange and the National Stock Exchange of India Limited on August 8, 2026. The company confirmed that all necessary statutory and regulatory formalities, including filings with the Registrar of Companies, are being completed.